Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-05. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
=== opal or umber mutations (UGA) === The third and last stop codon in the standard genetic code was discovered soon after, and corresponds to the nucleotide triplet "UGA". To continue matching with the theme of colored minerals, the third nonsense codon came to be known as "opal", which is a type of silica showing a variety of colors. Nonsense mutations that created this premature stop codon were later called opal mutations or umber mutations.
2 AgNO3 → 2 Ag + O2 + 2 NO2 Most metal nitrates thermally decompose to the respective oxides. This may be the case for silver nitrate. Unlike most metal oxides, however, silver oxide readily degrades to the elemental silver.
===== Temperature ===== Temperature has a multiplicity of effects on plants depending on a variety of factors, including the size and condition of the plant and the temperature and duration of exposure. The smaller and more succulent the plant, the greater the susceptibility to damage or death from temperatures that are too high or too low. Temperature affects the rate of biochemical and physiological processes, rates generally (within limits) increasing with temperature. However, the Van't Hoff relationship for monomolecular reactions (which states that the velocity of a reaction is doubled or trebled by a temperature increase of 10 °C) does not strictly hold for biological processes, especially at low and high temperatures. When water freezes in plants, the consequences for the plant depend very much on whether the freezing occurs intracellularly (within cells) or outside cells in intercellular (extracellular) spaces. Intracellular freezing usually kills the cell regardless of the hardiness of the plant and its tissues. Intracellular freezing seldom occurs in nature, but moderate rates of decrease in temperature, e.g., 1 °C to 6 °C/hour, cause intercellular ice to form, and this "extraorgan ice" may or may not be lethal, depending on the hardiness of the tissue. At freezing temperatures, water in the intercellular spaces of plant tissues freezes first, though the water may remain unfrozen until temperatures fall below 7 °C. After the initial formation of ice intercellularly, the cells shrink as water is lost to the segregated ice.
Sources: en.wikipedia.org
In 1982, founder Arch "Beaver" Aplin was a partner in the opening of a store in Clute, Texas, the first to bear the name "Buc-ee's". He formed the name Buc-ee's by combining his childhood nickname and the name of his Labrador Retriever, Buck; as well as the appeal of Ipana toothpaste's animated mascot, Bucky the beaver. Aplin was born in Southeast Texas. His father was born in Harrisonburg, northeast of Alexandria, Louisiana, where Arch's grandparents still lived as of 2019. Buc-ee's eventually expanded and opened its first travel center in Luling in 2003. In 2012, Buc-ee's opened its largest travel center in New Braunfels, Texas, on Interstate 35. The New Braunfels location was the largest convenience store in the world at 68,000 square feet (6,300 m2), but on June 26, 2023, the Sevierville, Tennessee, Buc-ee's opened, becoming the world's largest convenience store at 74,707 square feet (6,940.5 m2). The Sevierville store was narrowly surpassed in size by a new store in Luling, Texas, at 75,000 square feet (7,000 m2) on June 10, 2024, replacing the original Luling travel center, which was 35,000 square feet (3,300 m2). The New Braunfels location had the 2012 "Best Restroom in America" as named by Cintas. After significant expansion in the Greater Houston area and central Texas, the first Buc-ee's in the Dallas–Fort Worth metroplex opened in Terrell, Texas, on June 22, 2015. The travel center is three miles (4.8 km) west of the Shops at Terrell, a former Tanger Outlets center, on Interstate 20.
== Charges == On October 20, 2017, a week after the prison attack, the four prisoners – 28-year-old Mikel Brady, 29-year-old Wisezah Buckman, 30-year-old Jonathan Monk and 33-year-old Seth Frazier – were charged with murder for the killings they committed throughout the attack. In June 2018, it was confirmed that all the four accused would undergo separate trials for the 2017 prison murders. On October 13, 2018, District Attorney Andrew Womble confirmed that he would seek the death penalty for all the four inmates. Under North Carolina state law, the death penalty was the maximum sentence for first degree murder.
=== Recent history === An IRA bomb exploded near the railway station in March 1997, damaging signalling equipment. The original IRA message was confusing and led to the evacuation of the Wilmslow police station to the local leisure centre not far from the explosion. Nobody was hurt. In the general election of the same year, the parliamentary constituency of Tatton, in which Wilmslow falls, made headlines as part of the "sleaze" accusations levelled against the then Conservative Government. Tatton MP, Neil Hamilton, was accused of accepting cash for tabling Parliamentary questions; he was defeated subsequently in the election by independent candidate Martin Bell. Bell was supported in his door to door canvassing for votes by David Soul and served a single term as MP.
Sources: en.wikipedia.org
In 2015, filgrastim was included on the WHO Model List of Essential Medicines, a list containing the medications considered to be most effective and safe to meet the most important needs in a health system.
== Military campaigns in Syria and Jazira == Ubayd Allah fought for Marwan and his tribal allies against the Qaysi tribes led by al-Dahhak ibn Qays al-Fihri, the governor of Damascus, at the Battle of Marj Rahit in August 684. The Qays were routed and al-Dahhak killed. Ubayd Allah was put in command of Marwan's army which, during Marj Rahit, consisted of 6,000 men from a handful of loyalist tribes. According to Kennedy, Ubayd Allah "clearly intended to rebuild the Syrian army which had served Mu'awiya and Yazid I so well". In the aftermath of Marj Rahit, Ubayd Allah oversaw campaigns against rebel Qaysi tribes for Marwan and his son and successor Abd al-Malik (r. 685–705) in the Jazira. However, Marwan's forces were too little to assert Umayyad rule throughout the caliphate. Thus, Ubayd Allah expanded recruitment to include various Qaysi tribes. He placed Husayn ibn Numayr al-Sakuni of Kindah as his second-in-command, and Shurahbil ibn Dhi'l Kala' of Himyar, Adham ibn Muhriz of Bahila, Rabi'a ibn al-Mukhariq of Banu Ghani and Jabala ibn Abd Allah of Khath'am as deputy commanders. Other than Husayn ibn Numayr, all of the commanders were either Qaysi or had earlier supported al-Dahhak against Marwan. In January 685, as Ubayd Allah was in Manbij preparing for the Umayyad reconquest of Iraq, Husayn ibn Numayr defeated the pro-Alid Penitents at the Battle of Ayn al-Warda. Ubayd Allah had been promised by Marwan the governorship over all of the lands he could conquer from the Alids and Ibn al-Zubayr, and he may have been sanctioned to plunder Kufa.
These two drugs work synergistically and were found to be more effective than either drug alone. The development of nanotechnology and molecular biology has provided the improvement of nanomaterials with specific properties which are now able to overcome the weaknesses of traditional disease diagnostic and therapeutic procedures. In recent years, more attention has been devoted to designing and the development of new methods for realizing sustained release of diverse drugs. Since each drug has a plasma level above which is toxic and below which is ineffective and in conventional drug delivery, the drug concentration in the blood rises quickly and then declines, the main aim of an ideal drug delivery system (DDS) is to maintain the drug within a desired therapeutic range after a single dose, and/or target the drug to a specific region while simultaneously lowering the systemic levels of the drug. Graphene–based materials such as graphene oxide (GO) have considerable potential for several biological applications including the development of new drug release system. GOs are an abundance of functional groups such as hydroxyl, epoxy, and carboxyl on its basal surface and edges that can be also used to immobilize or load various biomolecules for biomedical applications. On the other side, biopolymers have frequently been used as raw materials for designing drug delivery formulations owing to their excellent properties, such as non-toxicity, biocompatibility, biodegradability and environmental sensitivity, etc.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.